Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b TPIP vs placebo in pulmonary arterial hypertension
jRCT2071220033Phase 2Completed
- Sponsor
- Insmed Incorporated
- Start
- Aug 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Treprostinil palmitil inhalation powder with Placebo (2 arms). Primary endpoint: Change from baseline in pulmonary vascular resistance at Week 16. Started Aug 2022; status: completed.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT2071220033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220033.